← Back to all protocols
18

Opioid Overdose & Naloxone InfusionToxicology/Withdrawal

Symptoms

  • Classic triad: reduced level of consciousness, respiratory depression (RR <10, especially <8) and pinpoint pupils
  • Also: hypoxia/cyanosis, bradycardia, hypotension, hypothermia, reduced bowel sounds; needle marks, patches or opioid packaging may be found
  • Fentanyl and analogues: rapid onset, chest wall rigidity possible. Pupils may not be pinpoint with hypoxia or with tramadol/pethidine; tramadol/pethidine can also cause seizures
  • Long-acting or modified-release opioids (methadone, buprenorphine, fentanyl, modified-release morphine/oxycodone) can cause prolonged or recurrent toxicity after naloxone wears off
  • Complications: aspiration, hypoxic brain injury, rhabdomyolysis, non-cardiogenic pulmonary oedema, acute withdrawal after naloxone in dependent patients

Investigations

  • Immediate ABC assessment: airway, respiratory rate, SpO2, AVPU/GCS, pulse, BP, temperature
  • Capillary glucose (hypoglycaemia mimic); VBG/ABG if hypoventilating (hypercapnia)
  • ECG (QT prolongation with methadone; arrhythmias with co-ingestants)
  • Paracetamol and salicylate levels, and consider co-ingestants (alcohol, benzodiazepines, other sedatives β€” naloxone will not reverse these)
  • U&E, creatine kinase if prolonged immobility; CXR if aspiration or pulmonary oedema suspected
  • Response to naloxone is both diagnostic and therapeutic; if no response after 10 mg total, question the diagnosis. Seek poison-centre/toxicology advice if uncertain

Treatment

  • Priority β€” airway and ventilation first: open airway, oxygen, bag-valve-mask ventilation if RR very low or SpO2 low; naloxone is an adjunct, not a replacement for airway support. Start CPR per ALS guidance if in cardiac arrest
  • Naloxone bolus β€” acute overdose (opioid-naive/unknown): Naloxone 400 micrograms to 2 mg IV; repeat every 2–3 min until adequate breathing; usual maximum 10 mg β€” if no response after 10 mg, reconsider the diagnosis. Effect appears within about 2 min IV and lasts roughly 1–4 h
  • If no IV access: Naloxone IM/SC (same doses) β€” slower onset but longer effect; intranasal 2–4 mg is an alternative
  • Low-dose titrated regimen (opioid-dependent, chronic/palliative opioid use, post-operative, or less life-threatening): Naloxone 100–200 micrograms (1.5–3 micrograms/kg) IV, then 100 microgram increments every 2 min until RR >8 and rousable to voice. Aim for adequate breathing rather than full wakefulness to avoid precipitating severe withdrawal
  • Why an infusion: naloxone acts for a shorter time than many opioids, so relapse into respiratory depression is common. Consider an infusion when repeated doses are needed to keep a good response (RR >8 and at least rousable to voice), or if a long-acting opioid is suspected or known (methadone, buprenorphine, fentanyl, modified-release morphine/oxycodone)
  • Preparing the infusion: Naloxone 4 mg (10 Γ— 400 microgram ampoules) made up to 20 mL with 0.9% sodium chloride = 200 micrograms/mL, via syringe pump
  • Starting rate: add up the total naloxone given (including pre-hospital doses) that produced a good response, then run 60% of that dose per hour. Table: 400 micrograms β†’ 240 micrograms/h = 1.2 mL/h; 800 β†’ 480 micrograms/h = 2.4 mL/h; 1200 β†’ 720 micrograms/h = 3.6 mL/h; 1400 β†’ 840 micrograms/h = 4.2 mL/h; 1600 β†’ 960 micrograms/h = 4.8 mL/h; 1800 β†’ 1080 micrograms/h = 5.4 mL/h; 2000 β†’ 1200 micrograms/h = 6.0 mL/h
  • Titrate and monitor: increase or decrease the rate according to response; record pump rate, AVPU and respiratory rate regularly on a chart, with continuous SpO2. If breathing falls again, re-bolus and increase the rate; if agitation/withdrawal or good wakefulness, reduce the rate. Stop when the opioid effect should have worn off
  • Withdrawal after naloxone: agitation, vomiting, sweating, tachycardia, hypertension, diarrhoea β€” usually short-lived; prevent by titrating the smallest effective dose, reassure, treat symptomatically; avoid restraint and watch for aspiration
  • Observation and disposition: monitor for at least 1–2 h after the last naloxone dose for short-acting opioids (local policy applies); observe much longer or admit for long-acting/modified-release opioids, buprenorphine, methadone or an ongoing infusion. Buprenorphine overdose may need higher naloxone doses
  • Other management: treat co-ingestions and complications (supplemental oxygen, fluids, hypotension, hypothermia, seizures); avoid activated charcoal unless the airway is protected; assess intent and mental health after any intentional overdose; before discharge give overdose-prevention advice, offer take-home naloxone and refer to addiction/mental health services
← Back to all protocols